NCT04231851View on ClinicalTrials.gov

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2027

Conditions
Acute Myelogenous Leukemia (AML) Due to TherapyAcute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions
DRUG

Glasdegib

Given PO

DRUG

CPX-351

Given IV

Trial Locations (4)

90095

University of California, Los Angeles, Los Angeles

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

94143

University of California, San Francisco, San Francisco

95817

University of California, Davis, Sacramento

Sponsors
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

University of California, Irvine

OTHER